藥明生物(02269.HK)年度純利增長10.5%至39.45億元
格隆匯3月25日丨藥明生物(02269.HK)宣佈,集團截至2024年12月31日止年度的收益同比增長9.6%,達人民幣18,675.4百萬元,其中非新冠收益同比增長13.1%。毛利同比增長12.1%至人民幣7,650.8百萬元,純利同比增長10.5%至人民幣3,945.4百萬元。
集團未完成訂單總量截至2024年12月31日達185億美元,包括未完成服務訂單105億美元以及未完成潛在里程碑付款訂單80億美元,同時集團三年內未完成訂單總額截至2024年12月31日達37億美元。
集團於2024年新增151個綜合項目,截至2024年12月31日綜合項目總數達817個,彰顯其可持續增長勢頭。集團的臨牀後期及非新冠商業化生產業務亦實現強勁增長,截至2024年12月31日項目數分別達66個及21個。特別是在報告期內,集團通過「贏得分子」戰略成功獲得20個外部項目,其中包括13個臨牀後期及商業化生產項目,爲未來收益增長奠定堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.